886 related articles for article (PubMed ID: 34891224)
21. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
23. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
Bachy E; Le Gouill S; Di Blasi R; Sesques P; Manson G; Cartron G; Beauvais D; Roulin L; Gros FX; Rubio MT; Bories P; Bay JO; Llorente CC; Choquet S; Casasnovas RO; Mohty M; Guidez S; Joris M; Loschi M; Carras S; Abraham J; Chauchet A; Drieu La Rochelle L; Deau-Fischer B; Hermine O; Gastinne T; Tudesq JJ; Gat E; Broussais F; Thieblemont C; Houot R; Morschhauser F
Nat Med; 2022 Oct; 28(10):2145-2154. PubMed ID: 36138152
[TBL] [Abstract][Full Text] [Related]
24. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
Jacobson CA; Locke FL; Ma L; Asubonteng J; Hu ZH; Siddiqi T; Ahmed S; Ghobadi A; Miklos DB; Lin Y; Perales MA; Lunning MA; Herr MM; Hill BT; Ganguly S; Dong H; Nikiforow S; Hooper M; Kawashima J; Xu H; Pasquini MC
Transplant Cell Ther; 2022 Sep; 28(9):581.e1-581.e8. PubMed ID: 35609867
[TBL] [Abstract][Full Text] [Related]
25. Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.
Loftager ASL; Danø A; Eklund O; Vadgama S; Hedlof Kanje V; Munk E
J Med Econ; 2023; 26(1):1303-1317. PubMed ID: 37725082
[TBL] [Abstract][Full Text] [Related]
26. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
Riedell PA; Hwang WT; Nastoupil LJ; Pennisi M; McGuirk JP; Maziarz RT; Bachanova V; Oluwole OO; Brower J; Flores OA; Ahmed N; Schachter L; Bharucha K; Dholaria BR; Schuster SJ; Perales MA; Bishop MR; Porter DL
Transplant Cell Ther; 2022 Oct; 28(10):669-676. PubMed ID: 35850429
[TBL] [Abstract][Full Text] [Related]
27. Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma.
Grana A; Gut N; Williams K; Maakaron J; Porter K; William BM; Vasu S; Penza S; Brammer JE; Saad A; Puto M; Jaglowski SM; Roddy J
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):238-245. PubMed ID: 33132101
[TBL] [Abstract][Full Text] [Related]
28. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
[TBL] [Abstract][Full Text] [Related]
29. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
Kelkar AH; Cliff ERS; Jacobson CA; Abel GA; Dijk SW; Krijkamp EM; Redd R; Zurko JC; Hamadani M; Hunink MGM; Cutler C
Ann Intern Med; 2023 Dec; 176(12):1625-1637. PubMed ID: 38048587
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Frank MJ; Hossain NM; Bukhari A; Dean E; Spiegel JY; Claire GK; Kirsch I; Jacob AP; Mullins CD; Lee LW; Kong KA; Craig J; Mackall CL; Rapoport AP; Jain MD; Dahiya S; Locke FL; Miklos DB
J Clin Oncol; 2021 Sep; 39(27):3034-3043. PubMed ID: 34133196
[TBL] [Abstract][Full Text] [Related]
31. Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Lunning MA; Wang HL; Hu ZH; Locke FL; Siddiqi T; Jacobson CA; Ahmed S; Miklos DB; Lin Y; Hill BT; Ghobadi A; Neelapu SS; Westin J; Dieyi C; Field P; Miao H; Shahani SA; Patel A; Spooner C; Fu C; Muramoto D; Xu H; Pasquini MC
Am J Hematol; 2024 May; 99(5):880-889. PubMed ID: 38504387
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
33. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
Sim AJ; Jain MD; Figura NB; Chavez JC; Shah BD; Khimani F; Lazaryan A; Krivenko G; Davila ML; Liu HD; Falchook AD; Dahiya S; Rapoport AP; Kim S; Locke FL; Robinson TJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1012-1021. PubMed ID: 31175906
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Elsawy M; Chavez JC; Avivi I; Larouche JF; Wannesson L; Cwynarski K; Osman K; Davison K; Rudzki JD; Dahiya S; Dorritie K; Jaglowski S; Radford J; Morschhauser F; Cunningham D; Martin Garcia-Sancho A; Tzachanis D; Ulrickson ML; Karmali R; Kekre N; Thieblemont C; Enblad G; Dreger P; Malladi R; Joshi N; Wang WJ; Solem CT; Snider JT; Cheng P; To C; Kersten MJ
Blood; 2022 Nov; 140(21):2248-2260. PubMed ID: 35839452
[TBL] [Abstract][Full Text] [Related]
35. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS; Jacobson CA; Ghobadi A; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy AH; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Bot AA; Shen RR; Dong J; Singh K; Miao H; Kim JJ; Zheng Y; Locke FL
Blood; 2023 May; 141(19):2307-2315. PubMed ID: 36821768
[TBL] [Abstract][Full Text] [Related]
36. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
Kato K; Fujii N; Makita S; Goto H; Kanda J; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Nakamura S; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
Int J Hematol; 2023 Mar; 117(3):409-420. PubMed ID: 36399286
[TBL] [Abstract][Full Text] [Related]
37. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson M; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Oluwole OO; Yakoub-Agha I; Khanal R; Rosenblatt J; Korn R; Peng W; Lui C; Wulff J; Shen R; Poddar S; Jung AS; Miao H; Beygi S; Jacobson CA
Blood; 2024 Feb; 143(6):496-506. PubMed ID: 37879047
[TBL] [Abstract][Full Text] [Related]
38. The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada.
Hillis C; Vicente C; Ball G
Pharmacoeconomics; 2022 Sep; 40(9):917-928. PubMed ID: 35844002
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
[TBL] [Abstract][Full Text] [Related]
40. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma.
Oluwole OO; Chen JMH; Chan K; Patel AR; Jansen JP; Keeping S; Zheng Y; Snider JT; Locke FL
Leuk Lymphoma; 2022 Dec; 63(13):3052-3062. PubMed ID: 36048026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
